Diazoxide Choline (Vykat XR) for Prader-Willi Syndrome-Associated Hyperphagia

The FDA has approved diazoxide choline extended-release tablets (Vykat XR – Soleno Therapeutics) for treatment of hyperphagia in patients ≥4 years old with Prader-Willi syndrome. Diazoxide choline is the first drug to be approved in the US for this indication. Diazoxide oral suspension (Proglycem) has been available for years for management of symptomatic hypoglycemia.

Publication Details

Journal: The medical letter on drugs and therapeutics/The medical letter
Published: 2025-04-28
DOI: https://doi.org/10.58347/tml.2025.1727e
Primary Topic: Genetic Syndromes and Imprinting
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Diazoxide Choline (Vykat XR) for Prader-Willi Syndrome-Associated Hyperphagia

Apr 28, 2025

The medical letter on drugs and therapeutics/The medical letter

Genetic Syndromes and Imprinting

article

Diazoxide Choline (Vykat XR) for Prader-Willi Syndrome-Associated Hyperphagia

April 28, 2025article en

Abstract

The medical letter on drugs and therapeutics/The medical letterVol. 67(1727)

Openalex Percentile: Top 90%

Genetic Syndromes and Imprinting

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Diazoxide Choline (Vykat XR) for Prader-Willi Syndrome-Associated Hyperphagia · The medical letter on drugs and therapeutics/The medical letter (2025) | TGRS Research Map | TGRS